Biotricity (NASDAQ:BTCY) & InspireMD (NYSE:NSPR) Critical Analysis

InspireMD (NYSE:NSPR) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.

Valuation and Earnings

This table compares InspireMD and Biotricity”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$7.78 million	10.29	-$19.92 million	($0.84)	-2.25
Biotricity	$12.06 million	0.87	-$14.09 million	($0.17)	-2.21

Biotricity has higher revenue and earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

InspireMD has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Profitability

This table compares InspireMD and Biotricity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
Biotricity	-80.42%	N/A	-188.47%

Analyst Ratings

This is a summary of recent ratings and target prices for InspireMD and Biotricity, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0	0	1	0	3.00
Biotricity	0	0	0	0	0.00

InspireMD presently has a consensus price target of $4.00, suggesting a potential upside of 111.64%. Given InspireMD’s stronger consensus rating and higher possible upside, research analysts plainly believe InspireMD is more favorable than Biotricity.

Insider and Institutional Ownership

44.8% of InspireMD shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 34.1% of InspireMD shares are held by company insiders. Comparatively, 10.1% of Biotricity shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.